Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast cancer (MBC)

被引：0
|
作者：
Winer, E
Batist, G
Harris, L
Hooftman, L
Park, Y
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Liposome Co, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
59O
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [41] Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer
    Flaherty, KT
    Malkowicz, SB
    Vaughn, DJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (02): : 136 - 139
  • [42] Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
    Shapiro, CL
    Ervin, T
    Welles, L
    Azarnia, N
    Keating, J
    Hayes, DF
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1435 - 1441
  • [43] Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m2 of doxorubicin (D).
    Munoz, E.
    Perez-Garcia, J. M.
    Saura, C.
    Vidal, M.
    Sanchez-Olle, G.
    Bellet, M.
    Gomez, P.
    Di Cosimo, S.
    Baselga, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
    Rivera, E
    Valero, V
    Arun, B
    Royce, M
    Adinin, R
    Hoelzer, K
    Walters, R
    Wade, JL
    Pusztai, L
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3249 - 3254
  • [45] Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study
    Collea, R. P.
    Kruter, F. W.
    Cantrell, J. E.
    George, T. K.
    Kruger, S.
    Favret, A. M.
    Lindquist, D. L.
    Melnyk, A. M.
    Pluenneke, R. E.
    Shao, S. H.
    Crockett, M. W.
    Asmar, L.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2599 - 2605
  • [46] A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
    Perez, EA
    Geeraerts, L
    Suman, VJ
    Adjei, AA
    Baron, AT
    Hatfield, AK
    Maihle, N
    Michalak, JC
    Kuross, SA
    Kugler, JW
    Lafky, JM
    Ingle, JN
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1225 - 1235
  • [47] A phase II study of bi-weekly pegylated liposomal doxorubicin and paclitaxel in metastatic breast canecer (MBC) patients (pts)
    Ferrari, Vittori D.
    Simoncini, Edda
    Amoroso, Vito
    Grisanti, Salvatore
    Valcamonico, Francesca
    Vassalli, Lucia
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    ANNALS OF ONCOLOGY, 2004, 15 : 49 - 49
  • [48] AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)
    Piccart, MJ
    Cufer, T
    Bruning, P
    Coleman, RE
    Calvert, HA
    Gamucci, T
    Twelves, C
    Duchateau, L
    Biganzoli, L
    Donato-di Paola, E
    Yague, C
    Epelbaum, R
    ANNALS OF ONCOLOGY, 2000, 11 : 155 - 155
  • [49] Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC)
    Mel, J. R., Sr.
    Ramos, M.
    Cueva, J.
    Castellanos, J.
    Almanza, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Prospective multicenter randomized phase III studies of weekly vs standard docetaxel (D2) plus doxorubicin (D4) for 1st line treatment of metastatic breast cancer (MBC)
    Stemmler, H. J.
    Herrmann, N.
    Heinemann, V.
    Vehling-Kaiser, U.
    Schaefer, M.
    Abenhardt, W.
    Kiechle, M.
    Harbeck, N.
    EJC SUPPLEMENTS, 2004, 2 (03): : 129 - 129
12345